Last reviewed · How we verify
commercially available lansoprazole
Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells.
Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells. Used for Erosive esophagitis, Gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome.
At a glance
| Generic name | commercially available lansoprazole |
|---|---|
| Also known as | once daily |
| Sponsor | Jason Lang, M.D., M.P.H. |
| Drug class | Proton pump inhibitor |
| Target | H+/K+ ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
This results in a decrease in gastric acid production, which can help alleviate symptoms of gastroesophageal reflux disease (GERD) and other conditions associated with excessive acid production. Lansoprazole works by covalently binding to the H+/K+ ATPase enzyme, preventing it from pumping protons into the gastric lumen and thereby reducing gastric acid secretion.
Approved indications
- Erosive esophagitis
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
- Duodenal ulcers
- Helicobacter pylori eradication
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Flatulence
Key clinical trials
- Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- commercially available lansoprazole CI brief — competitive landscape report
- commercially available lansoprazole updates RSS · CI watch RSS
- Jason Lang, M.D., M.P.H. portfolio CI